A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
Recruiting now · Phase 1
Conditions studied: Phase 1b, Open Label, REC-617, RB1-Negative, Leiomyosarcoma
In brief
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Key facts
- Study ID
- NCT07633756
- Run by
- M.D. Anderson Cancer Center
- People needed
- 15
- Starts
- 2026-10-19
- Expected to finish
- 2031-12-26
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.